The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine

American Journal of Emergency Medicine

Volumn 26, Issue 1, 2008, Pages 45-53

  Lozano, Hector ^a   Wu, Dongmei ^a   Bassuk, Jorge ^a   Aria, Jaqueline ^a   Kurlansky, Paul ^b   Lamas, Gervasio A ^a   Adams, Jose A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Florida Heart Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CELECOXIB; INDOMETACIN; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E2; TROPONIN I; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BLOOD GAS; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART ARREST; HEART EJECTION FRACTION; HEART FUNCTION; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; ISCHEMIA; MEDICAL INSTRUMENTATION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REPERFUSION INJURY; RESUSCITATION; SURVIVAL RATE; SWINE; TISSUE INJURY;

ANIMALS; CARDIOPULMONARY RESUSCITATION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; EPOPROSTENOL; HEART; HEART ARREST, INDUCED; HEART MASSAGE; INDOMETHACIN; MYOCARDIUM; PROSTAGLANDINS; PYRAZOLES; REGIONAL BLOOD FLOW; REPERFUSION INJURY; SULFONAMIDES; SWINE; TROPONIN I;

EID: 36849073171     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2007.10.004     Document Type: Article

References (62)

1. Antman E.M., DeMets D., and Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 5 (2005) 759-770
2. Gerritsen M.E. Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res 32 4 (1996) 720-732
3. Goetzl E.J., An S., and Smith W.L. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J 9 11 (1995) 1051-1058
4. Warner T.D., and Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18 7 (2004) 790-804
5. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56 3 (2004) 387-437
6. Melin J.A., and Becker L.C. Salvage of ischemic myocardium by prostacyclin during experimental myocardial infarction. J Am Coll Cardiol 2 2 (1983) 279-286
7. Bouchard J.F., Chouinard J., and Lamontagne D. Participation of prostaglandin E2 in the endothelial protective effect of ischaemic preconditioning in isolated rat heart. Cardiovasc Res 45 2 (2000) 418-427
8. Camitta M.G., Gabel S.A., Chulada P., Bradbury J.A., Langenbach R., Zeldin D.C., et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation (2001) 2453-2458
9. Veeravalli K.K., Akula A., and Kota M.K. Nitric oxide- and prostaglandin-mediated cardioprotection by bradykinin in myocardial ischemia and reperfusion injury. Pol J Pharmacol 55 6 (2003) 1021-1029
10. Watkins M.T., Al Badawi H., Russo A.L., Soler H., Peterson B., and Patton G.M. Human microvascular endothelial cell prostaglandin E1 synthesis during in vitro ischemia-reperfusion. J Cell Biochem 92 3 (2004) 472-480
11. Xiao C.Y., Hara A., Yuhki K., Fujino T., Ma H., Okada Y., et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104 18 (2001) 2210-2215
12. Xiao C.Y., Yuhki K., Hara A., Fujino T., Kuriyama S., Yamada T., et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109 20 (2004) 2462-2468
13. Alcindor D., Krolikowski J.G., Pagel P.S., Warltier D.C., and Kersten J.R. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology 100 3 (2004) 547-554
14. Timmers L., Sluijter J.P., Verlaan C.W., Steendijk P., Cramer M.J., Emons M., et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 115 3 (2007) 326-332
15. Jugdutt B.I. Effect of PGE1, PGE2 and PGI2 on ventricular arrhythmias during myocardial infarction in conscious dogs: relation to infarct size. Prostaglandins Med 7 5 (1981) 431-455
16. Jugdutt B.I. Prostaglandins in myocardial: with emphasis on myocardial preservation. Prostaglandins Med 7 2 (1981) 109-123
17. Wiklund L., Sharma H.S., and Basu S. Circulatory arrest as a model for studies of global ischemic injury and neuroprotection. Ann N Y Acad Sci 1053 (2005) 205-219
18. Nava G., Adams J.A., Bassuk J., Wu D., Kurlansky P., and Lamas G.A. Echocardiographic comparison of cardiopulmonary resuscitation (CPR) using periodic acceleration (pGz) versus chest compression. Resuscitation 66 1 (2005) 91-97
19. Adams J.A., Mangino M.J., Bassuk J., Kurlansky P., and Sackner M.A. Regional blood flow during periodic acceleration. Crit Care Med 29 10 (2001) 1983-1988
20. Carluccio E., Tommasi S., Bentivoglio M., Buccolieri M., Prosciutti L., and Corea L. Usefulness of the severity and extent of wall motion abnormalities as prognostic markers of an adverse outcome after a first myocardial infarction treated with thrombolytic therapy. Am J Cardiol 85 4 (2000) 411-415
21. Galasko G.I., Basu S., Lahiri A., and Senior R. A prospective comparison of echocardiographic wall motion score index and radionuclide ejection fraction in predicting outcome following acute myocardial infarction. Heart 86 3 (2001) 271-276
22. Klouche K., Weil M.H., Sun S., Tang W., and Kamohara T. Echo-Doppler observations during cardiac arrest and cardiopulmonary resuscitation. Crit Care Med 28 11 Suppl (2000) N212-N213
23. Smock A.L., Larson B., Brown C., and Conti C. Early prediction of 30-day mortality after Q-wave myocardial infarction by echocardiographic assessment of left ventricular function-a pilot investigation. Clin Cardiol 24 3 (2001) 191-195
24. Birnbaum Y., Ye Y., Rosanio S., Tavackoli S., Hu Z.Y., Schwarz E.R., et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65 2 (2005) 345-355
25. Bolli R., Shinmura K., Tang X.L., Kodani E., Xuan Y.T., Guo Y., et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 506-519
26. Mobert J., and Becker B.F. Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J Am Coll Cardiol (1998) 1687-1694
27. Nomura F., Matsuda H., Shirakura R., Ohtani M., Sawa Y., Nakano S., et al. Experimental evaluation of myocardial protective effect of prostacyclin analog (OP-41483) as an adjunct to cardioplegic solution. J Thorac Cardiovasc Surg 101 5 (1991) 860-865
28. Rossoni G., Muscara M.N., Cirino G., and Wallace J.L. Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol (2002) 1540-1546
29. Serebruany V.L., Herzog W.R., and Gurbel P.A. Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Prostaglandins Leukot Essent Fatty Acids 56 2 (1997) 135-142
30. Wainwright C.L., and Parratt J.R. Failure of cyclo-oxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion: implications for the role of prostaglandins as endogenous myocardial protective substances. Cardiovasc Res (1991) 93-100
31. Rossoni G., Manfredi B., De Gennaro Colonna V., Brini A.T., Polvani G., Clement M.G., et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol Res 53 4 (2006) 359-366
32. Strohmenger H.U., Lindner K.H., Keller A., Lindner I.M., Bothner U., and Georgieff M. Concentrations of prolactin and prostaglandins during and after cardiopulmonary resuscitation. Crit Care Med 23 8 (1995) 1347-1355
33. Hughes W.A., and Hughes S.C. Hemodynamic effects of prostaglandin E2. Anesthesiology 70 4 (1989) 713-716
34. Hyman A.L., Kadowtiz P.J., Lands W.E., Crawford C.G., Fried J., and Barton J. Coronary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with prostacyclin and other prostanoids. Proc Natl Acad Sci U S A 75 7 (1978) 3522-3526
35. Lopaschuk G.D., Michalak M., Wandler E.L., Lerner R.W., Piscione T.D., Coceani F., et al. Prostaglandin E receptors in cardiac sarcolemma. Identification and coupling to adenylate cyclase. Circ Res 65 3 (1989) 538-545
36. Woditsch I., and Schror K. Prostacyclin rather than endogenous nitric oxide is a tissue protective factor in myocardial ischemia. Am J Physiol 263 5 Pt 2 (1992) H1390-H1396
37. Shinmura K., Tang X.L., Wang Y., Xuan Y.T., Liu S.Q., Takano H., et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 97 18 (2000) 10197-10202
38. Johnson III G., Furlan L.E., Aoki N., and Lefer A.M. Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 66 5 (1990) 1362-1370
39. Smalling R.W., Feld S., Ramanna N., Amirian J., Felli P., Vaughn W.K., et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation 92 4 (1995) 935-943
40. Jugdutt B.I., Hutchins G.M., Bulkley B.H., and Becker L.C. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49 3 (1981) 685-700
41. Klein A.L., Wold L.E., and Ren J. The cyclooxygenase-2 product prostaglandin E2 modulates cardiac contractile function in adult rat ventricular cardiomyocytes. Pharmacol Res 49 (2004) 99-103
42. Krumnikl J.J., Bottiger B.W., Strittmatter H.J., and Motsch J. Complete recovery after 2 h of cardiopulmonary resuscitation following high-dose prostaglandin treatment for atonic uterine haemorrhage. Acta Anaesthesiol Scand 46 9 (2002) 1168-1170
43. Adderley S.R., and Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274 8 (1999) 5038-5046
44. Shinmura K., Tamaki K., Sato T., Ishida H., and Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol 288 5 (2005) H2093-H2101
45. Kuhn J.E., Steimle C.N., Zelenock G.B., and D'Alecy L.G. Ibuprofen improves survival and neurologic outcome after resuscitation from cardiac arrest. Resuscitation 14 4 (1986) 199-212
46. Capone M.L., Tacconelli S., Di Francesco L., Sacchetti A., Sciulli M.G., and Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82 1-4 (2007) 85-94
47. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 12 (2001) 2057-2072
48. Clement R., Das D.K., Engelman R.M., Otani H., Bandhyopadhyay D., Hoory S., et al. Role of a nonsteroidal anti-inflammatory agent, ibuprofen, in coronary revascularization after acute myocardial infarction. Basic Res Cardiol 85 1 (1990) 55-70
49. Jugdutt B.I., Hutchins G.M., Bulkley B.H., and Becker L.C. Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol 46 1 (1980) 74-82
50. Lucchesi B.R. Myocardial ischemia, reperfusion and free radical injury. Am J Cardiol 65 19 (1990) 14I-23I
51. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 9458 (2005) 475-481
52. Mollace V., Muscoli C., Masini E., Cuzzocrea S., and Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57 2 (2005) 217-252
53. Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 53 7 (1997) 576-582
54. Adams J.A., Bassuk J., Wu D., Lozano H., Kurlansky P., and Lamas G. Nitric oxide synthase isoform inhibition prior to whole body ischemia reperfusion in pigs: vital or protective?. Resuscitation 74 3 (2007) 516-525
55. Piana R.N., Shafique T., Dai H.B., and Sellke F.W. Epicardial and endocardial coronary microvascular responses: effects of ischemia-reperfusion. J Cardiovasc Pharmacol 23 4 (1994) 539-546
56. Messina E.J., Weiner R., and Kaley G. Prostaglandins and local circulatory control. Fed Proc 35 12 (1976) 2367-2375
57. Oltman C.L., Kane N.L., Miller Jr. F.J., Spector A.A., Weintraub N.L., and Dellsperger K.C. Reactive oxygen species mediate arachidonic acid-induced dilation in porcine coronary microvessels. Am J Physiol 285 6 (2003) H2309-H2315
58. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 6 (2001) 433-442
59. Levesque L.E., Brophy J.M., and Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142 7 (2005) 481-489
60. Steffel J., Luscher T.F., Ruschitzka F., and Tanner F.C. Cyclooxygenase-2 inhibition and coagulation. J Cardiovas Pharmacol 47 Suppl 1 (2006) S15-S20
61. Fiedler V.B. Role of arachidonic acid metabolites in cardiac ischemia and reperfusion injury. Pharmacotherapy 8 3 (1988) 158-168
62. Heindl B., and Becker B.F. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch Pharmacol 363 2 (2001) 233-240